PMID- 12900776
OWN - NLM
STAT- MEDLINE
DCOM- 20040504
LR  - 20181130
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 32
IP  - 4
DP  - 2003 Aug
TI  - Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves 
      neutrophil recovery after autologous marrow transplantation in rhesus macaques.
PG  - 399-404
AB  - Daily administration of filgrastim decreases the duration of severe neutropenia 
      in the clinical setting. A sustained-duration form of filgrastim, pegfilgrastim, 
      significantly reduces scheduling protocols to a single injection per chemotherapy 
      cycle while maintaining therapeutic efficiency. We examined the ability of a 
      single injection of pegfilgrastim to significantly improve neutrophil recovery 
      following autologous bone marrow transplantation (AuBMT) in rhesus macaques. On 
      day 1, postmyeloablation (920 cGy x-irradiation) and AuBMT, animals received 
      either 0.1% autologous serum for 18 consecutive days (n=13), or single doses of 
      pegfilgrastim via the subcutaneous (s.c.) or intravenous (i.v.) route (300 or 100 
      micro g/kg), or a single dose of filgrastim at 300 micro g/kg via the s.c. or 
      i.v. route, or filgrastim at 10 micro g/kg via the s.c. route (n=4) on a daily 
      basis (range=days 12-17). Pharmacokinetic parameters and neutrophil recovery were 
      assessed. A single dose of pegfilgrastim via the i.v. or s.c. route was as 
      effective as daily filgrastim administration, resulting in significant 
      improvement of neutrophil recovery after myeloablation and ABuMT. Effective 
      pegfilgrastim plasma concentrations were maintained in neutropenic animals until 
      after the onset of hematopoietic recovery. Enhanced pharmacokinetics in AuBMT 
      cohorts are consistent with self-regulating, neutrophil-mediated clearance.
FAU - Farese, A M
AU  - Farese AM
AD  - Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA.
FAU - Yang, B-B
AU  - Yang BB
FAU - Roskos, L
AU  - Roskos L
FAU - Stead, R B
AU  - Stead RB
FAU - MacVittie, T J
AU  - MacVittie TJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Cytokines)
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 3A58010674 (pegfilgrastim)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - PVI5M0M1GW (Filgrastim)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Bone Marrow Cells
MH  - Bone Marrow Transplantation/*methods
MH  - Cohort Studies
MH  - Cytokines/metabolism
MH  - Filgrastim
MH  - Granulocyte Colony-Stimulating Factor/*analogs & 
      derivatives/*pharmacokinetics/*pharmacology
MH  - Macaca mulatta
MH  - Male
MH  - Neutropenia
MH  - Neutrophils/drug effects/*metabolism
MH  - Polyethylene Glycols
MH  - Recombinant Proteins/metabolism
MH  - Time Factors
MH  - Transplantation Conditioning
MH  - Transplantation, Autologous
EDAT- 2003/08/06 05:00
MHDA- 2004/05/05 05:00
CRDT- 2003/08/06 05:00
PHST- 2003/08/06 05:00 [pubmed]
PHST- 2004/05/05 05:00 [medline]
PHST- 2003/08/06 05:00 [entrez]
AID - 1704156 [pii]
AID - 10.1038/sj.bmt.1704156 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2003 Aug;32(4):399-404. doi: 10.1038/sj.bmt.1704156.